AP
DYN icon

Aspect Partners’s Dyne Therapeutics DYN Stock Holding History

Aspect Partners’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.17K Buy
233
+8
+4% +$149 ﹤0.01% 406
2026
Q1 		$4.08K Hold
225
– – ﹤0.01% 391
2025
Q4 		$4.4K Sell
225
-380
-63% -$7.2K ﹤0.01% 399
2025
Q3 		$7.65K Buy
605
+580
+2,320% +$6.62K ﹤0.01% 350
2025
Q2 		$238 Hold
25
– – ﹤0.01% 594
2025
Q1 		$262 Sell
25
-700
-97% -$10K ﹤0.01% 586
2024
Q4 		$17.1K Hold
725
– – 0.01% 220
2024
Q3 		$26K Hold
725
– – 0.01% 162
2024
Q2 		$25.6K Hold
725
– – 0.02% 159
2024
Q1 		$20.6K Hold
725
– – 0.02% 178
2023
Q4 		$9.64K Buy
+725
New +$7.08K 0.01% 263

Other funds holding DYN

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
AFC
Ares Financial Consulting Calabasas, California $139M AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Aspect Partners's DYN Position: Q2 2026 in Review

Aspect Partners increased its Dyne Therapeutics (DYN) stake by 3.6% in Q2 2026, buying an estimated $149 and bringing the position to 233 shares worth $5.17K. The position accounts for ﹤0.01% of the portfolio, ranked #406.

Aspect Partners first reported a position in DYN in Q4 2023 and has held it in 11 quarters since. The position peaked at $26K in Q3 2024. 12 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Aspect Partners held 233 shares of Dyne Therapeutics worth $5.17K as of Q2 2026.
  • Aspect Partners bought 8 Dyne Therapeutics shares in Q2 2026, an estimated $149.
  • Dyne Therapeutics made up ﹤0.01% of Aspect Partners's portfolio in Q2 2026, its #406 holding.
  • Aspect Partners first reported a position in Dyne Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Aspect Partners's Dyne Therapeutics position peaked at $26K in Q3 2024.
  • 12 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Aspect Partners's 13F filing for Q2 2026, filed 16 Jul 2026.